March 15, 2022 4:51pm
As I had state yesterday, nibling on weakness was the way to go; right again if not early
Pre-open indications: 6 Hits and 3 Miss
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
The multiple metrics and Bottom Line say it all succinctly … just the facts
Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?
If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed UP +599.10 points (+1.82%); the S&P closed UP +89.34 points (+2.14%) while the Nasdaq closed UP +367.40 points (+2.92%)
Henry’omics:
Gains after pain while traders continued to eye the latest with ceasefire negotiations in Ukraine and China Covid lockdowns that could wreak havoc on tech supply chains.
February’s surge in energy prices led wholesale goods prices to their biggest one-month jump on record, the Labor Department reported Tuesday. The headline producer price index (PPI) rose 0.8% in February from the previous month. While that was slightly lower than the 0.9% estimated by Dow Jones, it still showed a 10% gain from the same time last year. <CNBC>
The market is now fully pricing in a rate hike of at least 25 basis points when the central bank makes its policy statement on Wednesday. Investors will also be closely watching the Fed's projections for the path of rate hikes this year and in coming years to rein in inflation. <Reuters>
52-week low:
· Precigen (PGEN) at $1.89
This a.m.’s post, RegMed Investors’ (RMi) pre-open: “cell and gene therapy sector, not lookin’ good” … https://www.regmedinvestors.com/articles/12341
RegMed/Stem/Cell and Gene therapy’s 36 covered equities’ Advance/Decline (A/D) lines: what happened …
- Tuesday opened positive at 26 up/9 downs, 2 flats, stayed positive at the mid-day at 20/14 and 2 flats, ending with a positive close of 28/6 and 1 flat;
Pre-open Indications: 6 Hits < Biostage (BSTG -$0.30), Beam Therapeutics (BEAM +$1.58), Global Blood Therapeutics (GBT +$0.36), Caribou Therapeutics (CRBU +$0.18), Editas Medicine (EDIT +$0.84), Precigen (PGEN +$0.02) > 3 Miss < Sage Therapeutics (SAGE +$0.62), CRISPR Therapeutics (CRSP +$1.59), Intellia Therapeutics (NTLA -$0.37),
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 … (ATHX) added
The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works as Tuesday expressed decline of -$0.30 with 380 shares traded after Monday’s flat with 28 shares traded, Friday’s 1,602 shares trading up +$0.39, Thursday -$0.63 with 488 shares traded, Wednesday -$0.26 with 1,225 shares traded and last Tuesday flat with 1,130 shares traded
- WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
- A “zombie” company funded by non-U.S. Beijing, China entities
- By use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering
- BSTG is NOT going ANYWHERE without a cash inflow.
Key Metrics:
- Tuesday - Sector volume was LOW with 4 of the 29-upside having higher than the 3-month average volume with LOW volume of 3 of 6-downside having higher than the 3-month average volume;
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Tuesday, the IBB was up +1.28% and the XBI was up +1.47%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Tuesday was down -1.94 points or -6.11% at 29.83
Jumping with share pricing momentum (10 of 28):
- CRISPR Therapeutics (CRSP +$1.98 after Monday’s -$3.36),
- Fate Therapeutics (FATE +$1.64 after Monday’s -$3.88),
- Beam Therapeutics (BEAM +$1.51 after Monday’s -$7.18),
- Ultragenyx (RARE +$1.49 after Monday’s -$3.21),
- Vericel (VCEL +$1.14 after Monday’s -$1.40),
- Alnylam Pharmaceuticals (ALNY +$1.12 after Monday’s -$3.16),
- Regenxbio (RGNX +$1.00 after Monday’s -$2.05),
- Editas Medicine (EDIT +$0.83 after Monday’s -$0.98),
- Sage Therapeutics (SAGE +$0.66),
- BioLife Solutions (BLFS +$0.54 after Monday’s -$2.12),
Hammered in today’s market (6 of 6):
- Intellia therapeutics (NTLA -$0.53 after Monday’s -$2.49),
- Biostage (BSTG -$0.30 after Monday’s -$0.30
- Homology Medicine (FIXX -$0.07),
- Verastem (VSTM -$0.03),
- Caladrius Biosciences (CLBS -$0.016),
- Solid BioSciences (SLDB -$0.0099),
Flat:
- Adverum Biotechnologies (ADVM)
March, Q1/2022:
- Tuesday closed positive with 28 incliners, 6 decliners and 1 flat
The BOTTOM LINE: The reality continues as investors remain very fearful on adding extra risk in this time of conflict uncertainty.
An appropriate quote, “Markets are psychological first and analytical second,” Revolution Growth partner Todd Klein. “Some of the cliches from the 1980s are reemerging, like Wall Street having to climb a wall of worry in order to have enough visibility into the future to invest with confidence.”
Gains have showed some life in the cell and gene therapy sector and I believe opening the door for a start to a rebound.
It’s not the whole picture – the sector needs an action item to offset the divergences to the bottoms.
As stated, uncertainty definitely surrounded the cell and gene therapy sector …
The sector was mostly lower, stripped equities of any upside (the downfall range was down -0.25% to -3.75% with the ups ranging from +0.57% to +9.58% from Monday’s downs of -0.32% to -14.89% while the upside placed its forward motion +1.52% to +10.91%.
The cell and gene therapy sector’s volume remained LOW.
Remember the adage, “It takes two to make a market"; that’s sellers and buyers.
I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.
Q4 and end-of-year earnings are still “gamy” than even I thought.
Earnings’ reporting coming:
· Athersys (ATHX), today
· Cellectis SA (CLLS) Tuesday, 3/22,
· Caladrius Biosciences (CLBS) Tuesday, 3/22
· Brainstorm Cell Therapeutics (BCLI), Monday, 3/28
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it defines purpose that takes courage, resolve and patience to stay the course of asking the questions without response!
